Patents by Inventor Margaret A. Lindorfer

Margaret A. Lindorfer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240117064
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 11, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240076397
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230399414
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 14, 2023
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D.CHAMULEAU, Tuna MUTIS
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11512137
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 29, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220251231
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: November 23, 2021
    Publication date: August 11, 2022
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11396553
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: July 26, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Antibody targeting cell surface deposited complement protein C3d and use thereof
    Patent number: 11384139
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 12, 2022
    Assignees: The United States of Americans represented by the Secretary, Department of Health and Human Services, University of Virginia Patent Foundation
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • ANTI-CD37 ANTIBODIES AND ANTI-CD20 ANTIBODIES, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210371539
    Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 2, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Ronald TAYLOR, Margaret LINDORFER, Hilma VAN DER HORST, Martine E. D. CHAMULEAU, Tuna MUTIS, Paul PARREN, Esther BREIJ
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210355232
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11034772
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: June 15, 2021
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210024647
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200291124
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: May 11, 2020
    Publication date: September 17, 2020
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200270359
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 27, 2020
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20190055305
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 21, 2019
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Virginia Patent Foundation,d/b/a University of Virginia Licensing & Ventures Group
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • Antibody targeting cell surface deposited complement protein C3d and use thereof
    Patent number: 10035848
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 31, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Virginia Patent Foundation
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20160333082
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • Enhancing the efficacy of immunotherapies by supplementing with complement
    Patent number: 7858087
    Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: December 28, 2010
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam Kennedy
  • Compositions and Methods for Regulating the Alternative Pathway of Complement
    Publication number: 20090004183
    Abstract: The present invention provides compositions and methods for regulating the alternative complement pathway.
    Type: Application
    Filed: July 25, 2005
    Publication date: January 1, 2009
    Inventors: Ronald P. Taylor, David John Dilillo, Margaret A. Lindorfer, Andrew W. Pawluczkowycz
  • Therapeutic uses of complement receptor 2
    Patent number: 7378094
    Abstract: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: May 27, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, William M. Sutherland
  • Enhancing the efficacy of immunotherapies by supplementing with complement
    Publication number: 20070298044
    Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.
    Type: Application
    Filed: July 25, 2007
    Publication date: December 27, 2007
    Inventors: Ronald Taylor, Margaret Lindorfer, Michael Solga, Adam Kennedy